Legion Health is an AI-native psychiatry practice that delivers world-class mental health care covered by insurance. The company automates the administrative work behind clinical care - and became the first to receive regulatory authorization for AI to prescribe psychiatric medications, starting in Utah.
Autobahn Therapeutics is a San Diego clinical-stage biotech building small-molecule medicines that reach the brain on purpose. Using a brain-targeting chemistry and prodrug platform, the company tunes where a drug goes - central versus peripheral - to unlock validated CNS biology that has been hard to drug safely. Its lead program, elunetirom (ABX-002), is an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist in Phase 2 trials for major depressive disorder and bipolar depression, backed by more than $200 million in venture funding and a 2026 FDA Fast Track designation.
CaaMTech is an Issaquah, Washington drug discovery company building patentable, psychedelic-inspired medicines. Founded in 2016 by chemist and patent attorney Andrew Chadeayne, it has synthesized and characterized a large library of novel tryptamines, solved crystal structures of compounds like 4-AcO-DMT and norpsilocin, and filed more than 100 patent applications. The company studies the 'entourage effect' in magic mushrooms to engineer compounds that keep the benefits while reducing side effects, and in 2021 raised a $22M Series A to push lead candidates toward human trials.
Circular Genomics is a San Diego biotechnology company turning circular RNA (circRNA) into a new class of blood-based biomarkers for brain health. Spun out of the University of New Mexico in 2021, the company uses brain-enriched circRNAs that cross the blood-brain barrier and stay stable in whole blood to detect and predict neurological and psychiatric conditions, from Alzheimer's disease to major depressive disorder. Its goal is to replace guesswork in brain care with measurable, actionable data, starting with early Alzheimer's detection and SSRI treatment-response testing for depression.
Blue Oak Pharmaceuticals is a Waltham, Massachusetts biotech founded in 2016 to discover the next generation of drugs for brain disorders. Led by neurobiologist and former Eli Lilly and Sunovion executive Tom Large, the company designs novel, CNS-focused 'privileged chemotypes' and pairs them with systems-neurobiology behavioral assays and AI to hunt first-in-class small molecules for schizophrenia, bipolar disorder and treatment-resistant depression. Its work runs through partnerships with phenotypic-screening firm PsychoGenics and AI drug-design company Exscientia.
Neural Galaxy (also operating as Galaxy Brain Scientific) is a Beijing-based brain science company building a precision, non-invasive neuromodulation platform. Its proprietary personalized Brain Functional Sectors (pBFS) technology maps over 200 functional regions of an individual brain, then guides targeted transcranial magnetic stimulation with millimeter accuracy. Founded in 2019 by Harvard and MIT neuroscientists with serial entrepreneur Coach Wei, the company is running clinical and registration trials across depression, Parkinson's, Alzheimer's, autism and aphasia, and has raised roughly $93M to date.
Brightside Health is a national virtual mental healthcare company delivering psychiatry, therapy and crisis care for people with depression, anxiety, and elevated suicide risk - powered by a proprietary AI platform and a 50-state clinician network, with coverage through major commercial insurers, Medicare and Medicaid.